TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Takeda Pharmaceutical Co ( (JP:4502) ) is now available.
Takeda Pharmaceutical reported a decline in its financial performance for the six-month period ending September 30, 2025, with significant decreases in revenue, operating profit, and net profit compared to the previous year. Despite the downturn, the company has adjusted its forecasts for the fiscal year ending March 31, 2026, indicating a slight recovery in operating profit and net profit, although core financial measures are expected to see a low-single-digit decline.
The most recent analyst rating on (JP:4502) stock is a Hold with a Yen4500.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
More about Takeda Pharmaceutical Co
Takeda Pharmaceutical Company Limited is a global leader in the pharmaceutical industry, focusing on innovative medicines and therapies. The company is listed on several stock exchanges including Tokyo, Nagoya, Sapporo, and Fukuoka, and is known for its commitment to research and development in the healthcare sector.
Average Trading Volume: 4,711,447
Technical Sentiment Signal: Buy
Current Market Cap: Yen6710.8B
Find detailed analytics on 4502 stock on TipRanks’ Stock Analysis page.